Under construction – not a live service
Sign in
Taking people in ChinaNo phase

Comparing MET and Gene Tests in Newly Diagnosed Non-Small Cell Lung Cancer

Compares tumor tests for MET and other genes in adults with untreated lung cancer.

Key facts

Who runs it
AstraZeneca
Where
Anyang, Baoding, Beijing, Cangzhou, Changzhi, Chengdu, Fuzhou, Guangzhou, Handan, Hefei, Huzhou, Jinan, Jining, Linhai, Linyi, Lishui, Liuzhou, Nanchang, Nanjing, Nanning, Nantong, Qiqihar, Shanghai, Shaoxing, Shenyang, Shenzhen, Shijiazhuang, Shiyan, Suining, Taiyuan, Tangshan, Tianjin, Weifang, Wenzhou, Wuhan, Wuhu, Xi'an, Xiamen, Xiangyang, Yangzhou, Zhoushan, and Zunyi, ChinaSee the 42 sites
Trial code
Registry title
A Study of MET Concordance and Gene Profiling in 1L NSCLC (Genomet)
Status
Recruiting
People taking part
1,000 people, planned
Started
2 Jun 2026
Expected to end
31 Mar 2027
Type of study
Interventional, 3 groups
Treatments tested
  • NGS testing
  • MET IHC testing
  • PD-L1 and Her2 testing
Record updated
26 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with advanced lung cancer (non-small cell type) who have not had treatment yet. It studies MET and tumor gene tests on their tumor tissue.

Age
18 years or older
Sex
All sexes can join.
Disease stage
Non-small cell lung cancer that cannot be removed by surgery and has spread locally (Stage IIIB/IIIC), spread further (Stage IV), or come back. It must be confirmed under the microscope.
Earlier treatment
No earlier radiotherapy or systemic therapy for this stage of the disease, except for first-line therapy started within 1 month before signing the consent form.
Biomarker or test result
No specific marker is required. People must give enough tumor tissue: at least 16 FFPE slides from a biopsy, or at least 13 FFPE slides from surgery within 2 years before consent.

Main reasons for not taking part

  • Another cancer now, or another invasive cancer in the past 5 years, with some exceptions
  • Earlier radiotherapy or systemic therapy for this stage of lung cancer, with one exception
  • Cannot give enough tumor tissue

The registry criteria, word for word

Show all 8 criteriaShow less

Who can take part

  • Participants are eligible to be included in the study only if all of the following criteria apply:
  • Age
  • Participant must be ≥ 18 at the time of signing the informed consent. Type of Participant and Disease Characteristics
  • Participants who are in accordance with the Eighth Edition of TNM Staging of Lung Cancer by the International Association for the Study of Lung Cancer and American Joint Committee on Cancer, histologically or cytologically confirmed unresectable locally advanced (Stage ⅢB/ⅢC), metastatic or recurrent (Stage IV) NSCLC
  • Willing to provide adequate tissue sample:; 1Biopsy tissue must be collected after confirmation of unresectable locally advanced (Stage IIIB/IIIC), metastatic, or recurrent (Stage IV) NSCLC diagnosis, and before initiation of any antitumor therapy. The biopsy specimens require at least 16 FFPE slides; or 2Surgical specimens only for patients with recurrent disease who either received no adjuvant therapy, or received only adjuvant chemotherapy and recurrence occurred >6 months after completing chemotherapy. The surgical specimens require at least 13 FFPE slides (surgical specimens obtained within 2 years before ICF signing); Informed Consent 4.Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the ICF and in this protocol; 5.Provision of signed and dated, written informed consent form prior to any mandatory study-specific procedures, sampling, and analyses

Who cannot take part

  • Prior radiotherapy or systemic therapy for unresectable locally advanced (Stage IIIB/IIIC) or metastatic/recurrent (Stage IV) NSCLC, except patients initiating first-line therapy for this specific disease stage within 1 month before ICF signing
  • Medical Conditions
  • Currently having other malignant tumors, or having other infiltrating malignant tumors in the past 5 years. Stage I malignant tumor after radical treatment for at least 3 years, except those considered by investigators to have a small possibility of recurrence. Participants with radically treated carcinoma in situ (non-infiltrating), papillary thyroid carcinoma and skin cancer other than malignant melanoma can be enrolled

Where in China

  • AnyangHospital not named in the registryTaking people
  • BaodingHospital not named in the registryTaking people
  • BeijingHospital not named in the registryTaking people
  • CangzhouHospital not named in the registryTaking people
  • ChangzhiHospital not named in the registryTaking people
  • ChengduHospital not named in the registryTaking people
  • FuzhouHospital not named in the registryTaking people
  • GuangzhouHospital not named in the registryTaking people
  • HandanHospital not named in the registryTaking people
  • HefeiHospital not named in the registryTaking people
  • HuzhouHospital not named in the registryTaking people
  • JinanHospital not named in the registryTaking people
  • JiningHospital not named in the registryTaking people
  • LinhaiHospital not named in the registryTaking people
  • LinyiHospital not named in the registryTaking people
  • LishuiHospital not named in the registryTaking people
  • LiuzhouHospital not named in the registryTaking people
  • NanchangHospital not named in the registryTaking people
  • NanjingHospital not named in the registryTaking people
  • NanningHospital not named in the registryTaking people
  • NantongHospital not named in the registryTaking people
  • QiqiharHospital not named in the registryTaking people
  • ShanghaiHospital not named in the registryTaking people
  • ShaoxingHospital not named in the registryTaking people
  • ShenyangHospital not named in the registryTaking people
  • ShenzhenHospital not named in the registryTaking people
  • ShijiazhuangHospital not named in the registryTaking people
  • ShiyanHospital not named in the registryTaking people
  • SuiningHospital not named in the registryTaking people
  • TaiyuanHospital not named in the registryTaking people
  • TangshanHospital not named in the registryNot yet recruiting
  • TianjinHospital not named in the registryTaking people
  • WeifangHospital not named in the registryTaking people
  • WenzhouHospital not named in the registryTaking people
  • WuhanHospital not named in the registryTaking people
  • WuhuHospital not named in the registryTaking people
  • Xi'anHospital not named in the registryTaking people
  • XiamenHospital not named in the registryTaking people
  • XiangyangHospital not named in the registryTaking people
  • YangzhouHospital not named in the registryTaking people
  • ZhoushanHospital not named in the registryTaking people
  • ZunyiHospital not named in the registryTaking people

About the trial

What the trial wants to find out

Multicenter prospective assessment of MET concordance and tumor gene profiling in treatment-naïve NSCLC

The 3 groups in the trial

  • cohort 1Other group

    Participants will be assigned to study cohorts based on the EGFR mutation status determined by central NGS testing. Only participants with EGFR mutations (EGFR 19del+/L858R+) will be included in Cohort 1.

    Treatment: NGS testing and MET IHC testing

  • cohort 2Other group

    Participants will be assigned to study cohorts based on the EGFR mutation status determined by central NGS testing.Those with no actionable genomic alterations (non-AGA), defined as EGFR 19del-/L858R-/20ins-/PACC-, ALK-, ROS1-, BRAF V600-, NTRK-, KRAS G12C-, MET amp-, MET exon14-, and RET-, will be assigned to Cohort 2.

    Treatment: NGS testing and PD-L1 and Her2 testing

  • cohort 3Other group

    Participants will be assigned to study cohorts based on the EGFR mutation status determined by central NGS testing.Those with other actionable genomic alterations (AGA, excluding EGFR 19del+/L858R+), defined as EGFR 20ins+, EGFR PACC+, ALK+, ROS1+, BRAF V600+, NTRK+, KRAS G12C+, MET amp+, MET exon14+, or RET+, will be assigned to Cohort 3.

    Treatment: NGS testing

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
A Multicenter, Prospective Study of MET Concordance and Gene Profiling in First-line Non-small Cell Lung Cancer (NSCLC) (Genomet)
Plain-language title
Comparing MET and Gene Tests in Newly Diagnosed Non-Small Cell Lung CancerGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
26 October 2026